Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV: * type of patient treated with VIMPAT® * VIMPAT® dose * Effect of VIMPAT® on evolution of seizure control * Persistence rate at 6 months in terms of treatment duration * Discontinuation rate * Description of any changes in other epilepsy therapies * Safety and tolerability
Study Type
OBSERVATIONAL
Enrollment
192
Unnamed facility
Aalst, Belgium
Unnamed facility
Antwerp, Belgium
Unnamed facility
Assebroek, Belgium
Unnamed facility
Mean Total Daily Dose of VIMPAT® (mg) at Baseline
Mean total daily dose at baseline will be only provided for subjects who were already treated by VIMPAT® at Baseline.
Time frame: Baseline
Mean Total Daily Dose of VIMPAT® (mg) at 3 Months
Time frame: 3 months
Mean Total Daily Dose of VIMPAT® (mg) at 6 Months
Time frame: 6 months
Galenic Formulation Repartition in Subjects Treated by VIMPAT® at Baseline
This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline. VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.
Time frame: Baseline
Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 3 Months
VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.
Time frame: 3 months
Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 6 Months
VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.
Time frame: 6 months
Percentage of Subjects Who Received Concomitant Antiepileptic Drug Treatment
Concomitant antiepileptic drug (AED) treatments are defined as treatments which started after or at the date of the first administration of VIMPAT®.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bruges, Belgium
Unnamed facility
Brussels, Belgium
Unnamed facility
Charleroi, Belgium
Unnamed facility
Duffel, Belgium
Unnamed facility
Ghent, Belgium
Unnamed facility
Hasselt, Belgium
Unnamed facility
La Louvière, Belgium
...and 7 more locations
Time frame: From baseline to study termination (6 months)
Treatment Persistence of VIMPAT® After 6 Months
Treatment persistence is defined as the percentage of subjects being treated under VIMPAT® after a given duration (\>=6 months).
Time frame: >=6 months
Percentage of Subjects by Category of Clinical Evolution of Seizure Control at Baseline
This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline. Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.
Time frame: Baseline
Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 3 Months
Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.
Time frame: 3 months
Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 6 Months
Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason
Time frame: 6 months